Promising combo targets CLL in untreated patients

NCT ID NCT04447768

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This study is testing a combination of two drugs, venetoclax and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) who have not yet had treatment. The goal is to see how well this therapy controls the disease and improves survival. About 100 fit adults with CLL will take part, and researchers will monitor their response and any side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Contacts and locations

Locations

Memorial Sloan Kettering Basking Ridge (All protocol activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All protocol activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All protocol activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau (All protocol activities)

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester (All protocol activities)

Harrison, New York, 10604, United States
Stanford University Medical Center (Data collection only)

Stanford, California, 94305-5408, United States
University of North Carolina

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.